Overview

The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

Status:
Terminated

Trial end date:
2021-06-15

Target enrollment:

Participant gender:

Summary

This is a 3-cohort, multicenter, Phase 1 study of the effect of tesetaxel, an investigational, orally administered taxane, on the corrected QT (QTc) interval and the potential effect of food, a cytochrome P450 (CYP) 3A inhibitor (itraconazole), and a CYP3A inducer (rifampin) on tesetaxel pharmacokinetics (PK) in adult patients with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Odonate Therapeutics, Inc.

Treatments:

Hydroxyitraconazole
Itraconazole
Rifampin